Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2024 16:05 ET | Source: Codexis, Inc.

Codexis to Report Second Quarter 2024 Financial Results on August 8

REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second...
July 01, 2024 16:05 ET | Source: Codexis, Inc.

Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with...
May 22, 2024 16:25 ET | Source: Codexis, Inc.

Codexis to Participate in Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare...
May 20, 2024 16:05 ET | Source: Codexis, Inc.

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled,...
May 14, 2024 06:00 ET | Source: Codexis, Inc.

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting

REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an...
May 02, 2024 16:05 ET | Source: Codexis, Inc.

Codexis Reports First Quarter 2024 Financial Results

Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer ...
April 18, 2024 16:05 ET | Source: Codexis, Inc.

Codexis to Report First Quarter 2024 Financial Results on May 2

REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first...
April 11, 2024 07:05 ET | Source: Codexis, Inc.

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s...
February 28, 2024 16:05 ET | Source: Codexis, Inc.

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected...
February 26, 2024 16:05 ET | Source: Codexis, Inc.

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an...